Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $3.4 million.

  • Fulcrum Therapeutics' Share-based Compensation fell 1197.28% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 2348.96%. This contributed to the annual value of $14.6 million for FY2024, which is 167.54% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Share-based Compensation of $3.4 million as of Q3 2025, which was down 1197.28% from $2.9 million recorded in Q2 2025.
  • Fulcrum Therapeutics' Share-based Compensation's 5-year high stood at $4.3 million during Q2 2024, with a 5-year trough of $2.1 million in Q1 2021.
  • In the last 5 years, Fulcrum Therapeutics' Share-based Compensation had a median value of $3.4 million in 2025 and averaged $3.3 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Share-based Compensation skyrocketed by 12617.77% in 2021, and later plummeted by 3381.68% in 2025.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Share-based Compensation stood at $3.8 million in 2021, then dropped by 13.76% to $3.3 million in 2022, then rose by 5.44% to $3.4 million in 2023, then dropped by 28.18% to $2.5 million in 2024, then skyrocketed by 35.65% to $3.4 million in 2025.
  • Its Share-based Compensation was $3.4 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.2 million in Q1 2025.